Thyroid cancer, Hurthle cell: Clinical Trials

7 trials for Thyroid cancer, Hurthle cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 3 active not recruiting. 7 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Active not recruiting 3
Phase 11Completed 1
Phase 31Active not recruiting 1

Follow Thyroid cancer, Hurthle cell: new trials by email Literature Review of Thyroid cancer, Hurthle cell trials Research Report on Thyroid cancer, Hurthle cell

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center192020-09-022026-09-17
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate - Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Phase 2CompletedAcademic and Community Cancer Research United572018-02-072025-08-29
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
sorafenib, everolimus - Refractory Hurthle Cell Thyroid Cancer
Phase 2Active not recruitingAlliance for Clinical Trials in Oncology352014-10-092026-02-11
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Cabozantinib S-malate, Laboratory Biomarker Analysis - Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)252013-05-082018-04-03
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation - Thyroid Cancer, Thyroid Neoplasms
Phase 2 / Phase 3Active not recruitingUniversity College, London5042012-06-262026-05-07
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis - Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)1272010-09-092021-07-15
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
AMG 706 - Thyroid Cancer
Phase 2CompletedAmgen1842005-07-012013-10-09

Narrower conditions

Adenocarcinoma, Follicular (6)  ·  Thyroid Cancer, Papillary (6)  ·  Thyroid Neoplasms (4)  ·  Adenoma, Oxyphilic (1)  ·  Carcinoma, Medullary (1)  ·  Thyroid cancer, follicular (1)

Broader conditions

Adenocarcinoma (6)  ·  Adenocarcinoma, Papillary (6)  ·  Carcinoma (6)  ·  Endocrine Gland Neoplasms (6)  ·  Endocrine System Diseases (6)  ·  Head and Neck Neoplasms (6)  ·  Neoplasms (6)  ·  Neoplasms by Histologic Type (6)  ·  Neoplasms by Site (6)  ·  Neoplasms, Glandular and Epithelial (6)  ·  Thyroid Diseases (6)  ·  Thyroid Neoplasms (2)  ·  Adenoma (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Neoplasms, Ductal, Lobular, and Medullary (1)

Interventions

Everolimus (1)  ·  Lenalidomide (1)  ·  Sodium Iodide (1)  ·  Sorafenib (1)  ·  cediranib (1)  ·  dabrafenib (1)  ·  lenvatinib (1)  ·  motesanib diphosphate (1)  ·  pembrolizumab (1)  ·  spartalizumab (1)  ·  trametinib (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Academic and Community Cancer Research United (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Amgen (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  University College, London (1)

Countries

United States (5)  ·  Canada (1)  ·  United Kingdom (1)

Top investigators

Alan L Ho, MD, PhD (1)  ·  Bryan R Haugen (1)  ·  Chih-Yi Liao (1)  ·  Eric Sherman, M.D. (1)  ·  Manisha Shah (1)  ·  Ujjal Mallick, MBBS MS FRCR (1)

Results publications

PMID 18596272, PMID 20739388, PMID 28817373, PMID 33720068, PMID 35078345, PMID 40543520

NIH funding

N01CM00071 (2), N01CM00099 (2), U10CA180821 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00100 (1), N01CM62201 (1), P30CA014599 (1), P30CA015083 (1), P30CA016058 (1), UM1CA186705 (1)